- Putin tells Merkel that Ukraine is on the brink of civil war
- San Antonio mayor to Obama: Give amnesty to illegals with legal families
- NYPD disbands unit that spied on Muslims to go after ‘real bad guys’
- Donald Rumsfeld has ‘no idea’ if he paid taxes correctly
- Bradley Manning named honorary grand marshal of San Francisco Pride parade
- Look out PayPal: Facebook working toward mobile payments system
- U.S. rebukes Iran’s U.N. envoy pick over 1979 embassy attack
- Stoned mom avoids jail after driving 12 miles with baby on roof
- More than 100 ‘inappropriate’ encounters between NYC school staffers, students since 2009: report
- Joe Biden to Boston bombing survivors: ‘America will never, ever stand down’
Experimental diet pill shows promise, little risk
ATLANTA (AP) - An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.
Arena Pharmaceuticals’ lorcaserin is one of three drugs that are boosting hope for a new generation of more effective weight-loss medicines. One gets a Food and Drug Administration review on Thursday and the others, later this year.
In the study, lorcaserin (lore-KASS-ah-rin) caused more people to lose at least 5 percent of their body weight over one year, more than twice the rate achieved by those on dummy pills.
Most people don’t stick to diets. And diet pills have had bad side effects or can’t be taken long-term. A low point came in 1997 when the popular “fen-phen” was pulled from the market after it was tied to heart valve problems.
But now comes lorcaserin, a round blue tablet that would be the first truly novel weight-loss pill in a dozen years if it wins approval. The drug targets the same appetite pathway fen-phen did but in a more selective, and perhaps safer, manner.
Results of a large company-funded study of it are in Thursday’s New England Journal of Medicine.
The study involved more that 3,100 obese or overweight people given either the drug or dummy pills.
After a year, nearly 48 percent of the lorcaserin group had lost at least 5 percent of their body weight _ about 13 pounds on average. Just 20 percent of the placebo group lost that much weight.
Only about half of those in the study stuck with it a year. That’s not unusual; diet studies typically have lots of dropouts. But more of the people on lorcaserin stayed in than those on placebo, suggesting that side effects were not a problem.
A second phase of the study began after one year with the original participants who remained. Those on dummy pills kept taking them, while the people on lorcaserin were assigned either to keep getting it or to switch to dummy pills. Neither they nor their doctors knew which treatment they were receiving.
Of those in the lorcaserin group who had lost at least 5 percent of their body weight in the first year of the study, about 68 percent who kept taking the drug kept the weight off, versus 50 percent of those switched to dummy pills.
Except for headaches and dizziness, side effects were essentially no worse with the drug than placebo. There was no higher rate of heart valve problems _ a key concern. However, larger studies are needed to conclusively rule out this risk.
Unlike some other obesity drugs, lorcaserin did not raise heart rates or blood pressure. In fact, cholesterol levels and other risk factors for heart disease improved in those on the drug.
“It looks very safe at this point,” said study leader, Dr. Steven Smith of the Sanford-Burnham Medical Research Institute in Orlando.
Some experts described the drug’s effectiveness as moderately good, and its safety as apparently very good. The findings are probably sufficient to meet FDA benchmarks and win approval, they predicted.
TWT Video Picks
By returning to goodness, the nation can achieve greatness once again
- Fuel-filled wings, ability to swarm: Pentagon offers glimpse at future of drone fleet
- Secret U.S. assessments show Afghanistan not ready to govern on own
- CARSON: Recovering Tocqueville's vision of American exceptionalism
- HURT: Wilson and Obama ... 100 years apart, but so alike
- 'Culture of intimidation' seen in Nevada ranch standoff
- U.S. military on high alert as Ukraine troops trade gunfire with pro-Russian militants
- GOP writes legislation to deny Attorney General Eric Holder his salary
- WEBER: Obamacare cuts home healthcare for millions of seniors
- HHS nominee Sylvia Burwell entangled in MetLife lawsuit
- Nevada Bundy ranch standoff could leave dirt on Harry Reid reputation
Celebrity deaths in 2014
Top 10 handguns in the U.S.
Chaos as Manhattan building explodes